Carson William E, Liang Margaret I
Division of Surgical Oncology, The Ohio State University School of Medicine, 410 West 10th Avenue, Columbus, OH 43210-1228, USA.
Surg Oncol Clin N Am. 2007 Oct;16(4):841-60, ix. doi: 10.1016/j.soc.2007.07.008.
Despite significant advances in the administration of combination cytotoxic chemotherapy, the overall 5-year survival rate is about 75% for a woman who has node-positive breast cancer, and metastatic disease is considered incurable. Recent advances in our understanding of the immune system have led to the hope that manipulation of this organ system could be used as a cancer treatment. Strategies that have been used in the immune therapy of breast cancer include the administration of exogenous cytokines, vaccines, and humanized monoclonal antibodies (mAb). Each of these approaches is discussed in turn in this article.
尽管在联合细胞毒性化疗的应用方面取得了重大进展，但对于患有淋巴结阳性乳腺癌的女性，其总体5年生存率约为75%，而转移性疾病被认为是无法治愈的。我们对免疫系统认识的最新进展带来了一种希望，即对这个器官系统进行调控可以用作癌症治疗方法。乳腺癌免疫治疗中使用的策略包括给予外源性细胞因子、疫苗和人源化单克隆抗体（mAb）。本文将依次讨论这些方法中的每一种。
